GASTROENTEROLOGYCLINICALLY ACTIONABLE RESULTS USING THE RIGHT TESTS, NOT THE MOST TESTS

G A S T R O E N T E R O L O G Y A T M A Y O C L I N I C

M A Y O M E D I C A L L A B O R A T O R I E S . C O M / G I

TESTING COMMITTED TO PROVIDING ANSWERS, NOT JUST RESULTS.At Mayo Clinic, we know the importance of

laboratory testing in a patient’s episode of

care. Our unique combination of specialized

laboratories and gastroenterology patient-care

clinics enables our clients to:

} Significantly reduce testing costs with cascading algorithmic approaches.

} Access comprehensive testing for celiac, inflammatory bowel disease (IBD), GI infections, GI cancers, and numerous other GI disorders from a single source.

} Evaluate and treat patients using the state-of-the-art diagnostic approaches.

} Receive rapid turnaround times on high-quality testing for their patients.

24/7 LAB SUPPORT AND BILLING SOLUTIONS } Mayo Laboratory Inquiry answers all calls personally, 24 hours a day, every day. We resolve more than 99% of inquiries with a single phone call.

} Dedicated support teams located in your region offer support on any laboratory matter.

} Our service and logistics experts guide you through reimbursement or other billing-related questions, including third-party billing and prior authorization.

} Testing committed to providing answers, not just results.

#1 Mayo Clinic’s rank in the 2015–16 U.S. News and World Report list of top Gastroenterology and GI Surgery Hospitals140

Digestive Disease Specialists on Staff—

One of the largest such groups in the world 107

Gastroenterology-related clinical trials currently open for enrollment

330+ Tests in our

Gastroenterology Test Catalog

9 Specialty groups within

the Department of Gastroenterology

and Hepatology at Mayo Clinic 386

Research articles published in 2014

BY THE NUMBERS

CASCADING APPROACHES FOR DEFINITIVE DIAGNOSIS OF CELIAC DISEASE

Working closely with our clinical and research GI colleagues, we have established several cascading algorithms to aid in the definitive diagnosis of celiac disease. These algorithms, each with a specific utility, automatically reflex to perform necessary tests with a single order.

Available Celiac Cascades:

} Celiac Disease Serology Cascade (Mayo Test ID: CDSP)

} Celiac Disease Comprehensive Cascade (Mayo Test ID: CDCOM)

} Celiac Disease Gluten-Free Cascade (Mayo Test ID: CDGF)

RAPID IDENTIFICATION OF THE CAUSATIVE AGENTS OF GI INFECTIONS

Mayo Clinic’s clinical microbiology laboratories span all areas of conventional and molecular microbiology and offer more than 200 tests designed for rapid identification of the causative agents of infectious diseases.

Our laboratories perform more than 2.8 million tests annually and have developed and implemented culture techniques, immunoassays, and nucleic acid and proteomic methods for rapid detection and identification of microbial pathogens.

COMPREHENSIVE TESTING FOR GI CANCERS

Our combination of targeted, single-gene test options and comprehensive next-generation sequencing (NGS) panels provides clinicians with flexible and cost-effective approaches to evaluating patients for GI cancers.

Furthermore, our genetic testing menu is focused on providing clinically actionable information, which enables clinicians to utilize potential therapies that target an individual’s specific tumor and molecular alterations, as well as identify and monitor other at-risk family members.

C U S T O M E R S E R V I C E F O R C L I N I C A L S P E C I A L I S T S / 8 5 5 - 5 1 6 - 8 4 0 4

USING FEWER TESTS FOR IBD DIAGNOSIS AND THERAPEUTIC MONITORING

DIFFERENTIATION BETWEEN IBD AND IBS Calprotectin is frequently used as part of the diagnostic evaluation of patients with suspected IBD, as elevated concentrations may be useful in distinguishing IBD from functional gastrointestinal disorders, such as irritable bowel syndrome (IBS).

DIAGNOSIS OF ULCERATIVE COLITIS AND CROHN’S DISEASE IN SUSPECTED IBD PATIENTS Our serology panel, which is based on significant peer-reviewed literature, examines only the characteristic patterns of antibodies with demonstrated clinical utility.

A NOVEL APPROACH TO THERAPEUTIC MONITORING OF INFLIXIMAB CONCENTRATIONS Measurement of infliximab concentrations helps guide clinicians in making treatment decisions for their IBD patients. Clinically significant antibodies-to-infliximab are found in patients with very low-trough infliximab concentrations in their serum. Therefore, a reflexive approach, which performs testing for antibodies-to-infliximab only when it is clinically relevant, benefits patients and reduces costs for the ordering institution.

MC2775-118

@mayocliniclabs/mayocliniclabsnews.mayomedicallaboratories.commayomedicallaboratories.com

COLLEGIAL ACCESS TO MAYO CLINIC CLINICIANS, LABORATORIANS, AND GENETIC COUNSELORS

When you partner with Mayo Medical

Laboratories, you extend your network to include

some of the world’s leading gastroenterology

experts. Mayo Clinic clinicians, laboratorians, and

genetic counselors are available to discuss testing

options, interpret results, or help with case review

and coordination.

FOR MORE INFORMATION ABOUT GASTROENTEROLOGY TESTING, VISIT:MayoMedicalLaboratories.com/GI